NEW YORK, NY (July 31, 2017) - A new technique developed by scientists at the New York Genome Center (NYGC) represents an important step forward for single-cell RNA sequencing, an advancing field of genomics that provides detailed insights into individual cells and makes it possible to distinguish between different cell types and to study disease mechanisms at the level of individual cells.
CITE-seq, or Cellular Indexing of Transcriptomes and Epitopes by sequencing, couples the measurement of surface protein markers on thousands of single cells with simultaneous sequencing of the messenger RNA (mRNA or transcriptomes) of those same single cells.
The NYGC researchers' proof-of-concept study of CITE-seq, published today in Nature Methods, monitored 10 surface proteins, together with transcriptomes, of 8,000 single cells, the largest scale demonstration of multidimensional single-cell analysis to date.
"No other method allows simultaneous measurements of transcriptomes and proteins on the same scale," said Marlon Stoeckius, PhD, a Research Scientist in the NYGC's Technology Innovation Lab, who led CITE-seq's development. "CITE-seq adds to already established methods for transcriptome analysis without any detrimental effects on the quality of the data generated."
Previous approaches relied on capturing protein information of individual cells by cytometry before depositing these cells onto plates for single-cell RNA sequencing. The current approaches suffer from a low throughput (the number of cells that can be analyzed) and are limited to a relatively small number of protein markers.
The protein detection component of CITE-seq is based on DNA-barcoded antibodies, which produce a sequencable readout that is captured along with the transcriptome of the cell. The integration of the protein and RNA data generated by CITE-seq required custom data analysis, which was developed in close collaboration with the lab of Rahul Satija, PhD, a Core Faculty Member at the NYGC. As an example of the power of CITE-seq, the investigators used the multimodal data to identify subclasses of natural killer (NK) cells that are difficult to distinguish based on transcriptomes alone.
The capacity of CITE-seq to more finely dissect cell populations has many potential applications in clinical research. "One possible future direction is to use CITE-seq on tumor samples to examine both individual tumor cells and the different pools of immune cells that infiltrate the tumor. This approach could be very useful in the deep characterization of tumor heterogeneity and in the development of new immunotherapeutic approaches," Dr. Stoeckius said.
The Technology Innovation Lab is a dedicated incubator within the NYGC comprised of a multidisciplinary team in which staff scientists and faculty, as well as many research collaborators, can explore and test breakthrough genomic tools and ideas. NYGC co-authors on the CITE-seq study include Christoph Hafemeister, PhD, Postdoctoral Research Associate, Satija Lab; William Stephenson, PhD, Senior Research Engineer, Technology Innovation; Brian Houck-Loomis, PhD, Manager, Technology Innovation; Harold Swerdlow, PhD, Vice President, Sequencing; Rahul Satija, PhD, Core Faculty Member and Assistant Professor at the Center for Genomics and Systems Biology, New York University; and Peter Smibert, PhD, Manager, Technology Innovation.
About the New York Genome Center
The New York Genome Center is an independent, nonprofit academic research institution at the forefront of transforming biomedical research with the mission of advancing clinical care. A collaboration of premier academic, medical and industry leaders across the globe, the New York Genome Center has as its goal translating genomic research into the development of new treatments, therapies and therapeutics against human disease. NYGC member organizations and partners are united in this unprecedented collaboration of technology, science and medicine, designed to harness the power of innovation and discoveries to advance genomic services. Their shared objective is the acceleration of medical genomics and precision medicine to benefit patients around the world. For more information, visit our website at http://www.
Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, Northwell Health, Princeton University, The Rockefeller University, Roswell Park Cancer Institute, Stony Brook University, Weill Cornell Medicine and IBM.
Director of Communications